Eosinophil fall within days; clinical benefit over weeks to months
Duration
Every 4 weeks
Mechanism of action
Humanized monoclonal antibody against interleukin-5 (IL-5), the main cytokine for eosinophil growth, activation and survival. Lowers blood and airway eosinophils.
Dosing
Adult
Asthma: 100 mg SC every 4 weeks
Pediatric
Asthma, age 6–11: 40 mg SC every 4 weeks
EGPA and HES use 300 mg every 4 weeks.
Indications
Severe asthma with an eosinophilic phenotype (age ≥6), as add-on maintenance
Eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, nasal polyps
Add-on maintenance in COPD with an eosinophilic phenotype (US approval 2025)